


“Potential safety concern” halts clinical trial of Eli Lilly antibody treatment

Image not found or type unknown



Pharmaceutical giant Eli Lilly has suspended clinical trials of its monoclonal antibody drug.
(Photo: Internet)

Indianapolis, October 14 (RHC)-- Pharmaceutical giant Eli Lilly has suspended clinical trials of its monoclonal antibody drug over an unspecified “potential safety concern.”

President Donald Trump touted a similar drug produced by Regeneron as a “cure” for COVID-19 after he received a dose while hospitalized at Walter Reed Medical Center earlier this month.

Both Eli Lilly and Regeneron have applied for emergency use authorizations of their antibody therapies.

<https://www.radiohc.cu/index.php/en/noticias/internacionales/236778-potential-safety-concern-halts-clinical-trial-of-eli-lilly-antibody-treatment>



Radio Habana Cuba